OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $114.22M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.17M
Average 0.37M
OKUR Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
OnKure Therapeutics, Inc.NASDAQ: OKUR
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 49.6% from a year ago
Property, plant & equipment (net) stood at $807K at the end of Q1 FY2026, down 49.6% from a year earlier and down 19.7% from the prior quarter. Over 3 fiscal years it compounded at -21.1% a year.
Context
- Property, plant & equipment (net) amounted to 0.4% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -49.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 1.01M USD
- Year-over-year change
- -44.0%
- 4-year CAGR
- +47.6%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.01M | -44.0% |
| FY2024 | 2024-12-31 | 1.8M | -6.0% |
| FY2023 | 2023-12-31 | 1.91M | -6.7% |
| FY2022 | 2022-12-31 | 2.05M | +865.6% |
| FY2021 | 2021-12-31 | 212K | — |
Property, Plant & Equipment (Net) vs competitors
How OKUR compares with its peers on the latest reported figures
- OKUR's Mar 2026 property, plant & equipment (net) of $807K is the 2nd highest of the 4 companies compared; the peer median is $700K.
- Its year-over-year change of -49.6% is the 3rd highest of 4, against a peer median of -20.9%.
- Property, plant & equipment (net) amounts to 0.4% of total assets for OKUR, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $7.47M | -14.4% | -15.1% | 4.6% | |
OKUROnKure Therapeutics, Inc. | Mar 2026 | $807K | -49.6% | -21.1% | 0.4% |
| Jun 2026 | $700K | -57.8% | -11.3% | 1.7% | |
| Mar 2026 | $228.57K | -20.9% | -22.7% | 0.9% | |
| Peer median (excluding OKUR) | $700K | -20.9% | -15.1% | 1.7% | |
Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 124.66M | 11.54M | 29.88M | 110.76M | 59.05M |
| Short-term Investments | 23.01M | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.06M | 840K | 0 | 0 | 1.79M |
| Total Current Assets | 153.73M | 13.62M | 33.77M | 113M | 60.84M |
| Property, Plant & Equipment (Net) | 212K | 2.05M | 1.91M | 1.8M | 1.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 78K | 329K | 58K | 109K | 273K |
| Total Non-current Assets | 290K | 2.38M | 1.97M | 1.9M | 1.28M |
| Total Assets | 154.02M | 16M | 35.73M | 114.91M | 62.12M |
| Account Payables | 0 | 2.52M | 3.42M | 2.97M | 1.43M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.2M | 1.46M | 1.66M | 3.17M | 1.25M |
| Total Current Liabilities | 6.2M | 5.54M | 7.29M | 10.53M | 5.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 167K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 444K | 64.39M | 129.83M | 0 | 12K |
| Total Non-current Liabilities | 611K | 64.88M | 130.29M | 549K | 12K |
| Total Liabilities | 6.81M | 70.42M | 137.58M | 11.08M | 5.93M |
| Common Stock | 3K | 1K | 0 | 1K | 1K |
| Retained Earnings | (84.73M) | (57.07M) | (102.05M) | (154.72M) | (214.24M) |
| Accumulated OCI | 34K | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 147.21M | (54.42M) | (101.84M) | 103.83M | 56.18M |
| Total Debt | 0 | 637K | 674K | 1.09M | 549K |
| Net Debt | (124.66M) | (10.91M) | (29.2M) | (109.68M) | (58.5M) |
OnKure Therapeutics, Inc.
NASDAQ:OKUR
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.